Norway· NO-ID_4E947840-308A-4DE7-8E96-E4938F77865F
Endoxan
A cyclophosphamide product containing cyclophosphamide, registered in Norway by Baxter. The same ATC class is registered in 17 of our 19 countries.
Checked against FEST (Norway) on
Informational only — not a medical device.
Where it is registered
Cyclophosphamide is registered in 17 of 19 countries.
Countries holding a registration under ATC L01AA01 (cyclophosphamide), each read from that country’s own register.
- This record: Norway, from FEST (Norway)
- 10 of them publish a price we can compare per daily dose
Cyclophosphamide · ATC L01AA01
17 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of cyclophosphamide costs, country by country.
Normalised to the WHO defined daily dose (0.25 g), the median price runs from $1.57 in France to $14.12 in Switzerland — a ×9.0 gap.
- 3 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Cyclophosphamide · price per daily dose (0.25 g)
USD · FX 28 Sept 2026
- CH Switzerland$14.12
- IT Italy$1.58
- FR France$1.57
The record
At a glance
FEST (Norway)- Active substance
- Cyclophosphamide
- Manufacturer
- Baxter
- Country
- Norway (NO)
- ATC code
- L01AA01
- ATC class
- Cyclophosphamide
- Defined daily dose
- 0.25 g, P
- Reimbursed
- Not published by this register
- Source register
- FEST (Norway)
- Last checked
- September 25, 2026
Packs & prices · 3
- no_merkevare_idID_4E947840-308A-4DE7-8E96-E4938F77865F
- no_varenummer3171391
- gtin4150003345281
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
541 interactions on record for cyclophosphamide.
Graded by severity as the source publishes them — 34 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Cyclophosphamide · interactions on record
541 records
- 34 severe
- 172 moderate
- 29 minor
- 304 info
Most severe, free to view
- Nalidixic acidJ01MB02severe
- CidofovirJ05AB12severe
- ThiotepaL01AC01severe
- CladribineL01BB04severe
2 more interactions with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Cyclophosphamide in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- PolandEndoxanBaxter Polska Sp. z o.o.
- United StatesCyclophosphamideCivica, Inc.
- United KingdomCyclophosphamide 1000mg/250ml in Sodium chloride 0.9% infusion bagsSpecial Order
- CzechiaCYCLOPHOSPHAMIDE ACCORDACCORD HEALTHCARE POLSKA Sp. z o.o., Varšava
- BelgiumCyclofosfamide Accord 1000 mgAccord Healthcare
- NetherlandsCyclofosfamide Accord 1000 mg, poeder voor oplossing voor injectie / infusieAccord Healthcare B.V.
- SpainCICLOFOSFAMIDA ACCORD 1.000 MG POLVO PARA SOLUCION INYECTABLE Y PARA PERFUSIÓN EFGAccord Healthcare S.L.U.
- FinlandCyclophosphamide AccordAccord Healthcare B.V.
Authorised across Europe · EMA
The same active substance is authorised in 29 EEA countries. Names it is sold under:
- Austria · Cyclophosphamid Sandoz, Endoxan
- Belgium · Cyclofosfamide Accord, Cyclophosphamide Hikma
- Bulgaria · Cyclophosphamide Sandoz, Ендоксан
- Cyprus · Cyclophosphamide Accord, Endoxan
- Czechia · Cyclophosphamide Accord, Endoxan
- Germany · Cyclophosphamid Accord, Cyclophosphamid Beta
- Denmark · Cyclophosphamide Accord, Cyclophosphamide Sandoz
- Estonia · Cyclophosphamide Accord, Endoxan
- Spain · Ciclofosfamida Accord, Ciclofosfamida Dr. Reddy
- Finland · Cyclophosphamide Accord, Sendoxan
- France · Cyclophosphamide Accord, Cyclophosphamide Reddy Pharma
- United Kingdom (Northern Ireland) · Cyclophosphamide Accord Healthcare, Cyclophosphamide Accord-Uk
- Greece · Endoxan
- Croatia · Ciklofosfamid Accord, Endoxan
- Hungary · Endoxan
- Ireland · Cyclophosphamide Monohydrate Seacross, Endoxana
- Iceland · Sendoxan
- Italy · Ciclofosfamide Accord, Cyclophosphamide Monohydrate Seacross
- Lithuania · Cyclophosphamide Accord Healthcare, Endoxan
- Luxembourg · Endoxan
- Latvia · Cyclophosphamide Accord, Endoxan
- Malta · Endoxana, Endoxana Injection
- Netherlands · Cyclofosfamide Accord, Cyclofosfamide Hikma
- Poland · Cyclophosphamide Accord, Cyclophosphamide Sandoz
- Portugal · Ciclofosfamida Accord, Ciclofosfamida Hikma
- Romania · Ciclofosfamidă Accord, Ciclofosfamidă Dr. Reddy’s
- Sweden · Cyclophosphamide Accord, Cyclophosphamide Sandoz
- Slovenia · Endoxan
- Slovakia · Endoxan
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FEST (Norway). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/abe3f42f-7d31-42ba-87cb-ded4fbb72bdf GET /v1/drugs/abe3f42f-7d31-42ba-87cb-ded4fbb72bdf?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Pulver til injeksjonsvæske, oppløsning",
"source": "fest",
"status": "A",
"atc_name": "Syklofosfamid",
"merkevare_id": "ID_4E947840-308A-4DE7-8E96-E4938F77865F",
"name_form_strength": "Endoxan pulv til inj væske, oppl 1 g",
"prescription_group": "C"
}See everything about cyclophosphamide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.